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Figure 1. Anti-PD-1 and anti-IL-6 treatment reduce tumor burden 
while their combination leads to clustered responses. 
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• Kras mutations are the most common oncogenic 
mutation in non-small cell lung cancer.​
• Unfortunately, targeting Kras directly has 
substantially failed thus far, and there are no 
therapies that adequately address most forms of 
mutant Kras.
• Immune checkpoint blockade, ICB (e.g., PD-1 
blockade) has shown promise patients with non-
small cell lung cancer.
• Our laboratory has previously shown that IL-6 
blockade reprograms the myeloid tumor 
microenvironment (TME), leading to a more robust 
cytotoxic immune response1.
• Accordingly, we hypothesized that there might be an 
additive/ synergistic effect of modulating the 
immunosuppressive TME and augmenting anti-
tumor immunity through combined PD-1 and IL-6 
blockade. We would also like to see the effectivity 
of anti-PD-1 treatment alone in Kras mutant lung 
cancer.
Figure 2. Increase in surface tumor number correlates with 
increased immunosuppressive hallmarks and weakened cytotoxic 
signature in combination treatment mice.
Figure 3. Flow cytometry analysis reveals a weaker 
cytotoxic immune response as surface tumor number 
increases in combination treatment mice.
Conclusions
• Consistent with previous results, anti-IL-6 
treatment results in decrease in tumor burden.
• Anti-PD-1 treatment significantly reduces tumor 
burden in our Kras-mutant lung cancer mouse 
model. 
• Personalized treatment with anti-IL-6 alone might 
be an alternative modality for ICB in patients with 
Kras mutant lung cancer.
• Combination treatment results in clustered 
responses, with some mice responding extremely 
well and others receiving no benefit.
• Responders in the combination treatment group 
have lower expression of Treg signatures and 
higher CD8 T-cell cytotoxic activation, as well as 
lower CXCL1 and higher PD1 expression.
Future Work
• More repeat experiments of each group 
• Dissection of why certain mice are responders or 
nonresponders will elucidate resistance 
mechanisms and help clinicians create 
individualized treatment strategies.
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